Sie sind bereits registriert?
Loggen Sie sich mit Ihrem Universimed-Benutzerkonto ein:
Sie sind noch nicht registriert?
Registrieren Sie sich jetzt kostenlos auf universimed.com und erhalten Sie Zugang zu allen Artikeln, bewerten Sie Inhalte und speichern Sie interessante Beiträge in Ihrem persönlichen Bereich zum späteren Lesen. Ihre Registrierung ist für alle Unversimed-Portale gültig. (inkl. allgemeineplus.at & med-Diplom.at)
Trastuzumab Fails as Adjuvant Therapy in Esophageal Cancer
Preoperative chemoradiotherapy with carboplatin and paclitaxel followed by surgery is the standard treatment for locally advanced esophageal adenocarcinoma. Targeting HER2-positive advanced esophagogastric adenocarcinoma with trastuzumab in the first- and second- or later-line settings has shown success, and a number of other promising agents are in development.
Investigators report an industry-supported, open-label, randomized, phase 3 trial evaluating the addition of trastuzumab to preoperative chemoradiotherapy in patients with HER2-positive esophageal or gastroesophageal junction adenocarcinoma. Patients with clinical T2–3 N0–1 disease testing positive for HER2 by immunohistochemistry or fluorescence in-situ hybridization were randomized to treatment with standard weekly paclitaxel, carboplatin, and 50.4 Gy of radiotherapy followed by surgery, or to the same treatment plus weekly trastuzumab during chemoradiotherapy, an additional dose of trastuzumab prior to surgery, and trastuzumab every 3 weeks for 13 cycles after surgery. Of 194 patients enrolled, most were men (84%) with T3 (79%) or node-positive disease (71%).
Median disease-free survival, the primary endpoint, did not differ between patients treated with or without trastuzumab (19.6 and 14.2 months; hazard ratio, 0.99; P=0.97), and estimated 2-, 3-, and 4-year DFS also did not differ. Similarly, median overall survival (38.5 and 38.9 months; HR, 1.04; P=0.85) and estimated 2-, 3-, and 4-year OS did not differ between groups. There was no difference in surgical outcomes, with similar rates of surgery (84% and 81%), achievement of R0 resection (98% and 100%), and pathologic complete response (27% and 29%). There were no new safety signals.
This important study indicates no survival benefit for the addition of trastuzumab to chemoradiotherapy and surgery in patients with HER2-positive esophageal or gastroesophageal junction adenocarcinoma. Alternative HER2-targeted combinations or other novel HER2-targeted agents need to be studied in the adjuvant and neoadjuvant space.
Safran HP et al.
Title: Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): A multicentre, randomised, phase 3 trial.
Source: Lancet Oncol 2022 Feb ; [e-pub]. (Abstract/FREE Full Text)